Publications by authors named "E deGoma"
Human Genetic Evidence to Inform Clinical Development of IL-6 Signaling Inhibition for Abdominal Aortic Aneurysm.
Arterioscler Thromb Vasc Biol
December 2024
Article Synopsis
- Abdominal aortic aneurysm (AAA) is a major health issue with no effective medical treatments, so researchers are exploring IL-6 signaling inhibition as a potential therapy.
- The study analyzed genetic data from large cohorts, finding strong associations between genetic variants linked to IL-6 signaling and reduced AAA risk.
- The results suggest that targeting IL-6 signaling could be a viable approach for AAA treatment, though it may not be effective for other aneurysm types.
Purpose Of Review: The objective of this narrative review is to summarize data from recently published prospective observational studies that analyze the association between circulating interleukin-6 (IL-6) levels and cardiovascular clinical or imaging endpoints.
Recent Findings: Higher levels of IL-6 are associated with a higher risk of cardiovascular death, major adverse cardiovascular events, myocardial infarction, stroke, peripheral artery disease, and heart failure. Imaging studies have also shown an association between IL-6 and carotid intima-media thickness progression, carotid plaque progression, severity, and vulnerability.
Purpose: Family-based cascade screening from index probands is considered an effective way of identifying undiagnosed individuals with familial hypercholesterolemia (FH). The role of genetic testing of the proband in the success of cascade screening for FH is unknown.
Methods: We randomized 240 individuals with a clinical diagnosis of FH to genetic testing for FH (n = 160) or usual care with lipid testing alone (n = 80).
Article Synopsis
- * In clinical trials, vadadustat showed significant improvements in hemoglobin levels after 6 weeks of treatment, with a majority of patients reaching target hemoglobin levels by week 16.
- * The treatment was generally well-tolerated, with some common side effects like nausea and hypertension, and the results suggest it is a promising option for managing CKD-related anemia.
Article Synopsis
- * In a Phase 2 trial with 94 participants, different dosing regimens of vadadustat were administered; however, no significant changes in hemoglobin levels were found during the study.
- * The drug was generally well tolerated, with 83% of participants experiencing adverse events, most commonly nausea and diarrhea, but no serious adverse events were linked to vadadustat, suggesting further research is needed.